Nasdaq
$1.85▼ 2.89%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $42.6MShares out 23.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.9After-hours26.10.10 05:05DEF 14AOther#●●●
Elicio Therapeutics, Inc.
Elicio Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for November 12, 2026, to vote on the election of directors and the ratification of its independent accounting firm. As of the record date of September 17, 2026, there were 27,091,187 shares of common stock outstanding, and shareholders may participate and vote via a virtual meeting portal.…more
$1.85-2.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14After-hours26.09.15 05:038-KKey event
Elicio Therapeutics, Inc.
Elicio Therapeutics has scheduled its 2026 annual meeting of stockholders for November 12, 2026. Consequently, the company has set a deadline of September 24, 2026, for the submission of stockholder proposals and director nominations.…more
$1.85-2.89%vs prev closeView filingShare - 9.2After-hours26.09.03 05:054Ownership
Elicio Therapeutics, Inc.
Insider Julian Adams of Elicio Therapeutics reported a change in beneficial ownership of securities effective August 31, 2026. This filing serves as an official record of the shift in the insider's equity holdings within the company.…more
$1.85-2.89%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:00#●●●#●●●
Elicio Therapeutics Reports Phase 2 Results for Pancreatic Cancer Candidate…more
Elicio Therapeutics announced that its Phase 2 study for a pancreatic cancer immunotherapy missed the primary endpoint, though it showed favorable trends in specific patient subgroups. The company plans to use these findings to refine its strategy for a potential Phase 3 trial.…more
$1.85-2.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.24Pre-market26.09.24 21:00
●●●●●●●● ●●●●● ●●●●●●
Elicio Therapeutics will present new analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer at the upcoming ESMO Congress. While the study previously missed its primary endpoint, the company aims to use these findings to refine its Phase 3 development strategy.…more
$1.85-2.89%vs prev close - 8.31Pre-market26.08.31 21:00
●●●●●●●● ●●●●● ●●●●●●
Elicio Therapeutics announced that its management will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. This event is a standard investor relations activity and does not provide immediate material impact on the stock.…more
$1.85-2.89%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report